Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2007 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: GEODON

« Back to Dashboard
Geodon is a drug marketed by Pfizer and Pfizer Inc and is included in three NDAs. It is available from eleven suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in GEODON is ziprasidone mesylate. There are nineteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.

Summary for Tradename: GEODON

Suppliers: see list11

Pharmacology for Tradename: GEODON

Clinical Trials for: GEODON

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Geodon in Weight Loss Study for Bipolar Disorders
Status: Completed Condition: Bipolar Disorder

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Geodon for the Treatment of Refractory Social Anxiety Disorder
Status: Completed Condition: Social Anxiety Disorder

Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
Status: Completed Condition: Depression; Bipolar Disorder

Ziprasidone in Pediatric Bipolar Disorder
Status: Completed Condition: Bipolar Disorder

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
Status: Completed Condition: Bipolar II Disorder; Major Depressive Episode

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Status: Completed Condition: Bipolar Disorder; Bipolar Depression; Depression

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
ziprasidone mesylate
INJECTABLE; INTRAMUSCULAR020919-001Jun 21, 2002RXYes4,831,031<disabled><disabled>
ziprasidone hydrochloride
CAPSULE; ORAL020825-002Feb 5, 2001RXNo6,245,766<disabled><disabled>
ziprasidone hydrochloride
CAPSULE; ORAL020825-003Feb 5, 2001RXNo6,245,766<disabled><disabled>
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION; ORAL021483-001Mar 29, 2006RXYes6,150,366<disabled><disabled>
ziprasidone hydrochloride
CAPSULE; ORAL020825-001Feb 5, 2001RXYes4,831,031<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: GEODON

Drugname Dosage Strength RLD Submissiondate
ziprasidone hydrochlorideCapsules20 mg, 40 mg, 60 mg and 80 mgGeodon2/7/2005
« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn